This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AFMD Affimed (AFMD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Affimed Stock (NASDAQ:AFMD) Get Affimed alerts:Sign Up Key Stats Today's Range$0.18▼$0.1850-Day Range$0.09▼$0.8352-Week Range$0.07▼$1.13VolumeN/AAverage Volume51.16 million shsMarket Capitalization$2.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. Read More Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AFMD Stock News HeadlinesOTC:AFMD.Q (Affimed)May 24, 2025 | fool.caAffimed Stock Price, Quotes and ForecastsMay 17, 2025 | benzinga.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation. | Paradigm Press (Ad)Cantor Fitzgerald cuts Affimed stock rating on insolvency newsMay 15, 2025 | investing.comAffimed N.V. Files for Insolvency Proceedings Amid Funding ChallengesMay 15, 2025 | nasdaq.comHC Wainwright & Co. Downgrades Affimed N.V. (AFMD)May 15, 2025 | msn.comAffimed N.V.: Affimed Announces Receipt of Nasdaq Delisting NoticeMay 14, 2025 | finanznachrichten.deAffimed (AFMD) Downgraded to Neutral by HC Wainwright & Co. | AFMD Stock NewsMay 14, 2025 | gurufocus.comSee More Headlines AFMD Stock Analysis - Frequently Asked Questions How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) announced its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.30) by $0.10. The biopharmaceutical company had revenue of $10.21 million for the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 193.84% and a negative net margin of 7,836.26%. Read the conference call transcript. When did Affimed's stock split? Affimed shares reverse split on the morning of Monday, March 11th 2024.The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Affimed IPO? Affimed (AFMD) raised $96 million in an initial public offering on Friday, September 12th 2014. The company issued 8,000,000 shares at a price of $11.00-$13.00 per share. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Affimed investors own include Meta Platforms (META), NVIDIA (NVDA), Novavax (NVAX), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/10/2021Today9/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AFMD CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees200Year Founded2000Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$114.66 million Net Margins-7,836.26% Pretax Margin-7,837.50% Return on Equity-193.84% Return on Assets-107.24% Debt Debt-to-Equity Ratio0.13 Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual Sales$877 thousand Price / Sales3.33 Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book0.04Miscellaneous Outstanding Shares16,100,000Free Float15,488,000Market Cap$2.92 million OptionableNo Data Beta2.07 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AFMD) was last updated on 9/6/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe trapdoor has a date on itRepublicans hold the House 220 to 215. Just three seats could flip control, and more than 35 GOP members have ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AFMD Stock Alerts